Patients see weight loss, lower blood pressure, better cholesterol numbers, and in many cases, they can cut back on other medications
The synergy between cagrilintide and GLP-1 agonists is particularly intriguing
Richele Corrado, one of our board-certified obesity medicine physicians at Revolution Medicine, explains: Zepbound can still be in your system at low doses for up to 30 days, due to its long half-life of about 5 days
Beyond GLP-1, the market encompasses peptide cancer therapies (Oncology Peptide Therapy at 4.1% share, 11.79% CAGR), somatostatin analogues for neuroendocrine tumours, GnRH agonists/antagonists for hormone-sensitive cancers, radioligand therapy, and reproductive medicine peptides each representing strategically important niches with their own competitive dynamics
Patients using TrumpRx.gov to purchase Novo Nordisks Wegovy and Eli Lilys Zepbound without insurance will pay about $350 per month for the injectables, and the price will be reduced to $250 per month over the next two years
Its marketed under brand names such as Wegovy, for weight management, and Ozempic, for managing type 2 diabetes